Data sourced from SEC EDGAR filings and third-party price providers. Scores, valuations, and metrics are algorithmic estimates. This is not investment advice. See our Terms and Methodology.
/
Data sourced from SEC EDGAR filings and third-party price providers. Scores, valuations, and metrics are algorithmic estimates. This is not investment advice. See our Terms and Methodology.
NextCell Pharma AB is a biopharmaceutical company focused on the development and commercialization of advanced stem cell therapies. Their primary purpose is to research and bring to market innovative treatments targeting diseases with unmet medical needs. NextCell Pharma AB is at the forefront of the biotechnology and healthcare sectors, particularly engaging in cellular therapies that are poised to revolutionize treatments in regenerative medicine. Their flagship product, ProTrans™, is under clinical trial for its efficacy in treating conditions like Type 1 diabetes. Based in Sweden, the company plays a significant role in the European biopharma landscape. Through strategic collaborations and cutting-edge research, NextCell Pharma AB aims to enhance therapeutic options and improve patient outcomes, marking its importance in modern medical treatments.
kr 0.08
kr 0.00 (-1.67%)
Live · 11:07 PM · Twelve Data
The business is unprofitable at the operating level (-401.30% margin). The thesis depends entirely on whether and when it reaches sustainable profitability.
Revenue declined 6.6% YoY. The question is whether this is cyclical or a structural shift.
ROIC dropped from -47.59% to -53.42%, capital efficiency is deteriorating.
Based on TTM earnings · Diluted shares
Profitability & Returns
Revenue (TTM)
kr 10M
▼ -6.6% YoY
Net Income (TTM)
-kr 39M
▲ +6.2% YoY
Op. Margin
-401.30%
▲ +3.5pp YoY
ROIC
-53.42%
▼ -5.8pp YoY
Cash Flow & Balance Sheet
FCF
N/A
Op. Cash Flow
N/A
Net Debt
-kr 26M
Net Cash Position
Cash & Equiv.
kr 26M
3Y CAGR: +21.2%
Continue Research
NextCell Pharma AB (NXTCL.XSTO)'s valuation is best read against its own history, its peers, and the growth its price implies. A high multiple is not the same as overvalued: fast-growing, high-quality businesses can deserve a premium. See the general approach in how to tell if a stock is overvalued.
On quality, NextCell Pharma AB scores 50/100 on Intrinsiqq's quality scorecard (a mixed business on these measures), weighing growth, margins, returns on capital, share count, and balance-sheet strength. All figures are computed from SEC filings; read the full . This is analysis, not investment advice.
NextCell Pharma AB scores 50 out of 100 on Intrinsiqq's quality score, a weighted blend of 5 metrics each scored 0 to 100, which makes it a mixed business on these measures. Recent fundamentals include a -401.3% operating margin and a -53.4% return on invested capital. The score weighs revenue and free-cash-flow growth, operating margins, return on invested capital, share-count change, and balance-sheet strength, all computed from SEC filings, not opinion. Because valuation only means something relative to quality, the full metric-by-metric breakdown is on the quality scorecard.
That depends on valuation and quality together, not either alone. you should weigh NXTCL.XSTO's valuation and scores 50/100 on quality (mixed). A cheap price is only a bargain if the business is durable, and a premium can be justified by genuine quality, so the two questions, "is it cheap?" and "is it good?", only make sense side by side. Read the valuation against the quality scorecard, run the DCF on your own assumptions, and decide for yourself. This is analysis from SEC filings, not investment advice.